2/19/2010

Swiss researchers discovered a class of antibiotics that targets Pseudomonas aeruginosa and other forms of drug-resistant, gram-negative bacteria by inhibiting a protein essential for developing the bacteria's outer cell membrane. Swiss biotech firm Polyphor is in discussions with drugmakers as it seeks to license POL7080, its lead drug candidate against Pseudomonas aeruginosa, said Michael Altorfer, the company's chief financial officer.

Full Story:
Yahoo!

Related Summaries